The landmark GY019 trial confirmed that letrozole alone is inferior to the standard of chemotherapy followed by letrozole maintenance. This was a surprising result for a chemo-resistant tumor, solidifying the need for chemotherapy in the adjuvant setting despite its limited effectiveness.

The traditional practice of classifying recurrent ovarian cancer as 'platinum-sensitive' or 'platinum-resistant' based on a six-month treatment-free interval is rapidly becoming obsolete. The introduction of maintenance therapies like PARP inhibitors is changing tumor biology and response patterns, suggesting this simple time-based distinction no longer adequately reflects the clinical reality.

Contrary to expectations, less common gynecologic cancers like low-grade serous, mucinous, and clear cell ovarian cancers are highly enriched with RAS/MAP kinase pathway mutations (40-70%). This contrasts with high-grade serous ovarian cancer, the most common subtype, which has fewer such mutations, making rare subtypes key targets for new therapies.

Even patients with "low-risk" advanced ovarian cancer face an 85% chance of recurrence. This high baseline risk justifies aggressive upfront combination therapies, like adding bevacizumab, to maximize the potential for a curative outcome without leaving any options off the table.

While RAS/MAP kinase alterations typically signify a more aggressive cancer with lower chemotherapy response, there's a notable exception. In low-grade serous ovarian cancers, patients with KRAS alterations may actually have a slightly better prognosis. This nuanced finding challenges the broad assumption that all RAS pathway mutations are purely negative prognostic markers.

Not all mutations are equal. PIK3CA alterations are often present from the start (truncal mutations), indicating a more aggressive cancer. In contrast, ESR1 mutations are typically acquired later as a direct mechanism of resistance to endocrine therapy, making repeat testing after disease progression crucial.

The RAS/MAP kinase pathway is an "underrecognized" and "underutilized" therapeutic target in endometrial cancers. Despite up to a quarter of these cancers having mutations in pathway genes, clinical focus has often been elsewhere. This highlights a significant, overlooked opportunity for applying RAS-targeted therapies to a broader patient population.

While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.

This cancer is a "low-shedding" tumor, making circulating tumor DNA (ctDNA) difficult to detect. A key study found only 32% of patients with measurable disease had detectable ctDNA, and the concordance for KRAS status with tumor sequencing was only 44%, mandating tissue-based testing.